Diagnos Submitted CARA System Request to FDA
The company filed a Section 513(g) Request for Information to clarify regulatory requirements for its CARA system.
Updated on Sept. 28, 2026 in Asthma
Live Poll
Should medical AI diagnostic systems undergo rigorous and standardized federal regulatory oversight?
Diagnos has submitted a Section 513(g) Request for Information to the U.S. Food and Drug Administration. The filing seeks to clarify the classification and regulatory path for its CARA System.
Why it matters
The submission follows a recommendation from the FDA to address specific regulatory needs. It represents a formal step by Diagnos to align its CARA System with the agency's requirements.
Diagnos submitted the request to the FDA following a prior Pre-Submission process to satisfy an agency recommendation. The exact regulatory classification for the CARA System remains under official review.
The players
Diagnos
This is a Brossard, Quebec-based technology company that develops screening and diagnostic solutions.
U.S. Food and Drug Administration
The federal agency is responsible for protecting public health by ensuring the safety and efficacy of medical devices.
The details
Headquartered in Brossard, Quebec, Diagnos is navigating the U.S. regulatory framework for its technology. This formal request is designed to determine the precise regulatory requirements necessary for the CARA System.
Timeline
September 28, 2026: Diagnos submitted the formal request to the FDA.
The Big Picture
This move follows the standard FDA Section 513(g) Request for Information process, which allows developers to obtain formal agency guidance on medical device classification. The submission marks a step toward reconciling the company's regulatory trajectory with established federal protocols.
The regulatory process determines how and when new diagnostic technologies can be made available to patients. Updates regarding the CARA System will clarify potential access timelines for its use in clinical settings.
The takeaway
Formal regulatory filings help companies ensure their technology meets all required safety and quality standards before market entry. These administrative steps are essential for the long-term viability of medical diagnostic tools.
Further reading
For more on diagnostic developments in respiratory health, visit the Asthma section.
Live Poll
Should medical AI diagnostic systems undergo rigorous and standardized federal regulatory oversight?
